Pages

▼

Thursday, 19 January 2017

New disulfiram trial in Sweden

DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial

This is a randomized phase 2/3 trial with an expected recruitment of 142 patients recruiting in Norway and soon to be recruiting at multiple centers in Sweden.

One arm gets standard alkylating chemotherapy at recurrence, and the other arm gets standard chemotherapy plus disulfiram and copper.


at

1 comment:

  1. Stephen W12 March 2017 at 17:59

    A proprietary form of disulfiram + copper has been granted orphan drug status by the FDA for GBM.

    http://www.cantex.com/content/therapeutic-targets/cx02-for-glioblastoma.htm
    https://clinicaltrials.gov/ct2/show/NCT03034135

    ReplyDelete